The August 4th show features a live interview with:
Immune Therapeutics Inc.
(Stock Symbol: IMUN),
CEO Noreen Griffin,
Dr Jay Ellenby and
Dr Gloria Herndon
Visit The Corporate Site — ImmuneTherapeutics.com
See Corporate Investors Information and stock quote page:
Listen To Show Replay Part 1:
Listen To Show Replay Part 2 with Immune Therapeutics Interview:
Immune Therapeutics is a specialty pharmaceutical company undergoing a wide range of FDA testing of therapeutic protocols preparatory to the manufacture, commercialization, marketing, and distribution of their patented therapies.
Their novel concepts entail enhancing and refining both the activation and modulation of the body’s natural immune system.
Low Dose Naltrexone used as an immune modulator
Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications (link to LDN patents), is currently used as an immune modulator.
See Report — Click Here
Medical Stocks to Buy August 2015
The biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using our patented immunotherapy.
Their Products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
The company’s therapies have been demonstrated over time to be highly efficacious and virtually free of side negative effects.
Small Cap Medical Stock News
Partnership with GB Pharma and AHAR sign LOI with Fidson Healthcare Plc for the distribution of Lodonal in Nigeria Announced.
Immune Therapeutics Inc. in partnership with GB Pharma Holdings Inc and American Hospitals & Resort [AHAR], announces that they have signed a Letter of Intent with Nigerian public company, Fidson Healthcare Plc [NSE:FIDSON.LG] one of Nigeria’s leading pharmaceutical companies. — See News
Immune Therapeutics Inc, Announces the official publication announcement of the NAFDAC approved 90-Day Bridging Trial of Lodonal™ with HIV/AIDS Patients.
Immune Therapeutics Inc – Lodonal™ an Adjunct Immune Therapy for Treatment of Patients with HIV/AIDS
Immune Therapeutics Inc. through its fully owned subsidiary, TNI Biotech International, today announced the dosing of the first patient with Lodonal™ (Once-daily Oral Treatment) for the 90-Day bridging clinical trial of Immune Therapeutics’ proprietary patented therapy (Lodonal™) as an adjunct treatment for HIV/AIDS and opportunistic infections. — See More
Immune Therapeutics Inc. CEO Issues Letter to Shareholders Highlighting Significant Progress — See News
Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. — See News
MoneyInfo Show Airs
10 AM to 11 AM EDT
Use this Link To Watch The Show:
Be On The Air With Us
Call In Your Questions
The Princeton Research Money Info show features where to invest now, stock market, business, economy and financial investment news.
The show is broadcast live on the internet and on the air from the studios of Radio Station WPSL AM 1590, Port St. Lucie, Florida — The Talk of the Treasure Coast
Money Info is hosted by investing experts Mike King and Charles Moskowitz together with radio broadcasting professional Greg Wyatt.
Stocks to Buy August 2015 on Investment News Show